Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC)
Aethlon Medical (Nasdaq: AEMD) has secured two significant patents for its Hemopurifier® device: U.S. Patent No. 12,409,260 for Long COVID treatment and European Patent 4136453 for COVID-19-associated coagulopathy (CAC) treatment. The U.S. patent, which expires in 2042, covers treating patients with reduced viral load but persistent Long COVID symptoms and the removal of circulating COVID-19 spike protein. The European patent, expiring in 2041, protects the Hemopurifier's use in treating CAC patients without circulating viral particles.
The U.S. patent received an additional 385-day term adjustment. CEO James Frakes emphasized that while the Hemopurifier® remains in R&D for Long COVID applications, these patents strengthen their intellectual property portfolio in areas with significant unmet medical needs.
Aethlon Medical (Nasdaq: AEMD) ha ottenuto due brevetti rilevanti per il dispositivo Hemopurifier®: il brevetto statunitense n. 12.409.260 per il trattamento del Long COVID e il brevetto europeo 4136453 per il trattamento della coagulopatia associata al COVID-19 (CAC). Il brevetto USA, con scadenza nel 2042, riguarda il trattamento di pazienti con ridotta carica virale ma sintomi persistenti di Long COVID e la rimozione della proteina spike circolante del SARS-CoV-2. Il brevetto europeo, in scadenza nel 2041, tutela l'uso dell'Hemopurifier nel trattamento dei pazienti con CAC in assenza di particelle virali circolanti.
Al brevetto USA è stato inoltre aggiunto un periodo di proroga di 385 giorni. Il CEO James Frakes ha sottolineato che, sebbene l'Hemopurifier® sia ancora in fase di ricerca e sviluppo per le applicazioni sul Long COVID, questi brevetti rafforzano il loro portafoglio di proprietà intellettuale in ambiti con importanti esigenze mediche non soddisfatte.
Aethlon Medical (Nasdaq: AEMD) ha asegurado dos patentes significativas para su dispositivo Hemopurifier®: la patente estadounidense Nº 12.409.260 para el tratamiento del COVID prolongado (Long COVID) y la patente europea 4136453 para el tratamiento de la coagulopatía asociada al COVID-19 (CAC). La patente estadounidense, que expira en 2042, cubre el tratamiento de pacientes con carga viral reducida pero síntomas persistentes de Long COVID y la eliminación de la proteína spike circulante del COVID-19. La patente europea, con vencimiento en 2041, protege el uso del Hemopurifier en el tratamiento de pacientes con CAC sin partículas virales circulantes.
La patente estadounidense recibió además una extensión de término de 385 días. El director ejecutivo James Frakes enfatizó que, si bien el Hemopurifier® sigue en I+D para aplicaciones en Long COVID, estas patentes fortalecen su cartera de propiedad intelectual en áreas con necesidades médicas significativas no cubiertas.
Aethlon Medical (나스닥: AEMD)는 Hemopurifier® 장치에 대해 두 건의 주요 특허를 확보했습니다: 롱코비드(장기 코로나) 치료를 위한 미국 특허 제12,409,260호와 COVID-19 관련 응고장애(CAC) 치료를 위한 유럽 특허 4136453호입니다. 2042년에 만료되는 미국 특허는 바이러스 부하는 감소했으나 롱코비드 증상이 지속되는 환자 치료와 순환하는 COVID-19 스파이크 단백질 제거를 대상으로 합니다. 2041년에 만료되는 유럽 특허는 순환하는 바이러스 입자가 없는 상태의 CAC 환자 치료에 Hemopurifier의 사용을 보호합니다.
미국 특허에는 추가로 385일의 기간 연장이 부여되었습니다. 제임스 프레이크스(James Frakes) CEO는 Hemopurifier®가 롱코비드 적용을 위해 여전히 연구개발 단계에 있지만, 이러한 특허들이 중대한 미충족 의료 수요가 있는 분야에서 지적 재산 포트폴리오를 강화한다고 강조했습니다.
Aethlon Medical (Nasdaq: AEMD) a obtenu deux brevets importants pour son dispositif Hemopurifier® : le brevet américain n° 12 409 260 pour le traitement du Long COVID et le brevet européen 4136453 pour le traitement de la coagulopathie associée au COVID-19 (CAC). Le brevet américain, qui expire en 2042, couvre le traitement des patients présentant une charge virale réduite mais des symptômes persistants de Long COVID ainsi que l'élimination de la protéine spike circulante du COVID-19. Le brevet européen, expirant en 2041, protège l'utilisation de l'Hemopurifier dans le traitement des patients atteints de CAC sans particules virales circulantes.
Le brevet américain a également bénéficié d'une prolongation de 385 jours. Le PDG James Frakes a souligné que, bien que l'Hemopurifier® soit encore en R&D pour des applications liées au Long COVID, ces brevets renforcent leur portefeuille de propriété intellectuelle dans des domaines présentant des besoins médicaux importants non satisfaits.
Aethlon Medical (Nasdaq: AEMD) hat zwei bedeutende Patente für sein Hemopurifier®-Gerät gesichert: das US-Patent Nr. 12.409.260 für die Behandlung von Long COVID und das europäische Patent 4136453 für die Behandlung von COVID-19-assoziierter Koagulopathie (CAC). Das US-Patent, das 2042 ausläuft, deckt die Behandlung von Patienten mit reduzierter Virenlast, aber anhaltenden Long-COVID-Symptomen sowie die Entfernung des zirkulierenden COVID-19-Spike-Proteins ab. Das europäische Patent, mit Ablauf 2041, schützt die Anwendung des Hemopurifier bei der Behandlung von CAC-Patienten ohne zirkulierende Virenpartikel.
Dem US-Patent wurde zusätzlich eine Fristverlängerung von 385 Tagen gewährt. CEO James Frakes betonte, dass das Hemopurifier® zwar noch in der F&E für Long-COVID-Anwendungen ist, diese Patente jedoch ihr geistiges Eigentum in Bereichen mit erheblichem ungedecktem medizinischem Bedarf stärken.
- Secured two strategic patents in US and Europe for Hemopurifier treatment applications
- Long patent protection periods extending to 2041-2042
- Additional 385 days of patent term adjustment granted for US patent
- Expanded intellectual property protection in areas with significant market potential
- Hemopurifier remains in research and development stage for Long COVID applications
- No immediate revenue impact as treatments are not yet commercialized
The 260 Patent is intended to protect the use of the Hemopurifier® in
The 453 Patent is intended to protect the use of the Hemopurifier® for the treatment of patients that lack circulating COVID-19 viral particles but exhibit COVID-19-associated CAC.
The 260 Patent was granted an additional 385 days of patent term due to patent term adjustment and will expire in 2042. The 453 Patent will expire in 2041.
"We believe securing these patents expands and strengthens our intellectual property portfolio in areas of significant unmet medical need," said James Frakes, CEO and CFO of Aethlon. "While the Hemopurifier® remains in the research and development stage relating to Long COVID, these protections position us well as we continue advancing potential future applications. Our goal is to build a strong foundation of innovation that could one day translate into meaningful treatment options for patients."
About the Hemopurifier®
The Aethlon Hemopurifier® is an investigational medical device designed to remove enveloped viruses, fragments of viruses, and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viral proteins. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses, fragments of viruses, and extracellular vesicles has been demonstrated in both in vitro studies and in human patients.
The Hemopurifier® holds a
The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.
About Aethlon Medical, Inc.
Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in
For more information, visit www.AethlonMedical.com and follow the Company on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties, and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to raise additional capital on terms favorable to the Company, or at all; the Company's ability to successfully complete development of the Hemopurifier; the Company's ability to successfully demonstrate the utility and safety of the Hemopurifier in cancer and infectious diseases, COVID-19 and in the transplant setting; the Company's ability to achieve and realize the anticipated benefits from operational and financial milestones; the Company's ability to obtain approval from the Ethics Committee of its third location in
Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
View original content:https://www.prnewswire.com/news-releases/aethlon-medical-announces-issuance-of-hemopurifier-patents-for-the-treatment-of-long-covid-and-covid-19-associated-coagulopathy-cac-302544201.html
SOURCE Aethlon Medical, Inc.
FAQ
What patents did Aethlon Medical (AEMD) receive for its Hemopurifier device?
When do Aethlon Medical's new Hemopurifier patents expire?
What conditions will Aethlon Medical's Hemopurifier be used to treat under these patents?
Is Aethlon Medical's Hemopurifier currently available for Long COVID treatment?
What additional patent term did Aethlon Medical receive for its US patent?
